FAK

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2672 PF-00562271 <1 mg/mL 14 mg/mL <1 mg/mL
S2890 PF-562271 <1 mg/mL 100 mg/mL <1 mg/mL
S2013 PF-573228 <1 mg/mL 26 mg/mL <1 mg/mL
S2820 TAE226 (NVP-TAE226) <1 mg/mL 94 mg/mL <1 mg/mL
S2725 PF-03814735 <1 mg/mL 0.4 mg/mL <1 mg/mL
S8523 GSK2256098 <1 mg/mL 82 mg/mL 82 mg/mL
S7357 PF-562271 HCl <1 mg/mL 100 mg/mL <1 mg/mL
S7653 PND-1186 (VS-4718) <1 mg/mL 24 mg/mL <1 mg/mL
S7644 PF-431396 <1 mg/mL 100 mg/mL <1 mg/mL
S7654 Defactinib (VS-6063, PF-04554878) <1 mg/mL 5 mg/mL <1 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2672

PF-00562271

PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

S2890

PF-562271

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

S2013

PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.

S2820

TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.

S2725

PF-03814735

PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.

S8523New

GSK2256098

GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM.

S7357

PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

S7653

PND-1186 (VS-4718)

PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.

S7644

PF-431396

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.

S7654

Defactinib (VS-6063, PF-04554878)

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

Tags: FAK activation | FAK signaling | FAK cancer | FAK phosphorylation | Focal Adhesion Kinase cancer | Focal Adhesion Kinase signaling | FAK inhibition | Focal Adhesion Kinase activation | Focal Adhesion Kinase phosphorylation | FAK assay | FAK inhibitor clinical trial | FAK cleavage | FAK inhibitor review